An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Curio Bioscience (CURIO) is a leading innovator in the life sciences industry, offering high-precision tools. Their Curio Seeker product enables whole transcriptome, spatial mapping of fresh frozen tissue at industry-leading resolution. The company is facing litigation from 10x Genomics (TXG) but is confident in their defense against patent infringement allegations.
Positive
None.
Negative
Facing litigation from 10x Genomics (TXG)
Potential legal costs and distractions from defending against allegations
PALO ALTO, Calif.--(BUSINESS WIRE)--
Curio Bioscience is a leading innovator of high-precision tools for the life sciences industry. Our Curio Seeker product enables whole transcriptome, spatial mapping of fresh frozen tissue at industry-leading resolution and represents the next stage of innovation from our team's inventions of the microarray, stochastic barcoding (unique molecular identifiers), and single cell and spatial tagging and analysis. Our team's inventions of spatial localization of biological targets using barcoding were documented over 15 years ago.
We believe that fair competition is a key component to innovation, and we embrace the motivation that it provides for creating the newest and highest-performing products for our customers, while keeping experiment costs reasonable and pushing the frontiers of science to the greatest extent possible.
Some companies do not share this sentiment. We have become the latest target in a string of attacks by a company (10x Genomics, NASDAQ: TXG) with a history of bringing litigation against smaller, innovating companies.
We are confident that we do not infringe the patents that 10x is asserting against us and believe that they will be found invalid. We will vigorously defend against 10x’s allegations.
